[Human testing of the nuclear spin tomographic contrast medium gadolinium-DTPA. Tolerance, contrast affect and the 1st clinical results].
In an initial clinical trial we examined the tolerance and the influence exercised on signals in nuclear magnetic resonance tomography by gadolinium-DTPA. In an open study, 4 dosages between 0.005 and 0.25 mmol Gd-DTPA/kg body-weight were tested on 5 healthy volunteers each. To ensure renal elimination of Gd-DTPA, NMR images were produced (0.35 T Magnetom) visualising the kidneys and urinary bladder before and more than 60 minutes after application of the contrast medium. The article shows in what manner the image is influenced by the dosage of the contrast medium and also by the time interval elapsing between injection of the contrast medium and production of the NMR tomogram. - Finally, first clinical results of NMR tomography contrast medium application are demonstrated in the case of 5 patients with cerebral tumours.
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D005682:Gadolinium / Q000008:administration & dosage; D006801:Humans; D007668:Kidney / Q000033:anatomy & histology; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D004369:Pentetic Acid / Q000008:administration & dosage; D014054:Tomography / Q000379:methods*; D001743:Urinary Bladder / Q000033:anatomy & histology
D003287:Contrast Media; D004338:Drug Combinations; D004369:Pentetic Acid; D005682:Gadolinium
Prüfung des kernspintomographischen Kontrastmittels Gadolinium-DTPA am Menschen. Verträglichkeit, Kontrastbeeinflussung und erste klinische Ergebnisse.